Etiology and Diagnostic Approach to Hypercalcemia

Primary Hyperparathyroidism (PHPT)

Primary hyperparathyroidism is defined by autonomous, excessive secretion of parathyroid hormone despite elevated serum calcium, indicating a PTH‑dependent cause of hypercalcemia. 1
More than 80 % of patients with PHPT have a single parathyroid adenoma, while multigland disease accounts for roughly 15–20 % of cases. 2

In patients with lung cancer, malignancy‑related hypercalcemia carries a poor prognosis, with a median survival of approximately one month after diagnosis. 3
Hypercalcemia is observed in 10–25 % of individuals with cancer, occurring most frequently in squamous cell carcinoma of the lung. 3
The humoral form (PTHrP‑mediated) is characterized by suppressed intact PTH (<20 pg/mL) together with elevated PTH‑related protein levels. 3

Multiple myeloma produces localized osteolytic hypercalcemia through direct bone invasion and secretion of osteoclast‑activating factors. 4

Certain lymphomas (especially non‑Hodgkin’s lymphoma) generate excess 1,25‑dihydroxyvitamin D, leading to increased intestinal calcium absorption; laboratory pattern shows suppressed PTH, low/normal 25‑OH vitamin D, and elevated 1,25‑OH vitamin D. 1

Granulomatous disorders such as sarcoidosis cause hypercalcemia via unregulated extra‑renal 1‑α‑hydroxylase activity in activated macrophages, producing a laboratory profile of suppressed PTH, low 25‑OH vitamin D, and high 1,25‑OH vitamin D. 1

Excessive vitamin D supplementation (doses >10 000 IU/day) can precipitate hypercalcemia through markedly increased intestinal calcium absorption. 4
High‑dose calcium supplementation (>2 000 mg/day) combined with absorbable alkali can lead to milk‑alkali syndrome, characterized by hypercalcemia, metabolic alkalosis, and renal insufficiency. 1
Calcitriol and vitamin D analogues (e.g., paricalcitol) induce hypercalcemia in 22.6–43.3 % of patients in clinical trials. 4
The potassium binder patiromer may cause hypercalcemia due to its calcium‑sorbitol counter‑ion that exchanges calcium for potassium in the colon. 4

Small‑cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is associated with hypercalcemia in approximately 60 % of cases, likely owing to tumor expression of PTHrP. 5

Secondary hyperparathyroidism arises when chronic kidney disease–related hypocalcemia and/or hyperphosphatemia stimulate PTH production, yet the kidneys cannot restore normal calcium levels. 2
Tertiary hyperparathyroidism develops after prolonged secondary hyperparathyroidism (commonly post‑kidney transplantation) and is marked by autonomous PTH secretion despite rising serum calcium, resulting in hypercalcemic hyperparathyroidism. 2

The first laboratory step in evaluating hypercalcemia is measurement of intact PTH to distinguish PTH‑dependent (e.g., PHPT, familial hypocalciuric hypercalcemia) from PTH‑independent causes (e.g., malignancy, granulomatous disease, vitamin D intoxication). 1
Corrected calcium should be calculated to account for hypo‑albuminemia:
Corrected Ca (mg/dL) = Total Ca + 0.8 × [4.0 – Serum albumin (g/dL)]. 4
Simultaneous assessment of both 25‑hydroxyvitamin D and 1,25‑dihydroxyvitamin D is recommended to differentiate vitamin D intoxication (high 25‑OH, normal 1,25‑OH) from granulomatous disease (low 25‑OH, high 1,25‑OH). 4
Parathyroid imaging should not be performed before confirming the biochemical diagnosis; imaging is reserved for surgical planning after a definitive biochemical work‑up. 1

Tumor secretion of parathyroid hormone‑related protein (PTHrP) mimics normal PTH, driving excessive osteoclast‑mediated bone resorption and raising serum calcium levels in patients with metastatic disease. 6
Metastatic tumor cells within bone release cytokines (e.g., interleukins, prostaglandins) that up‑regulate RANKL production by osteoblastic cells, thereby activating osteoclasts and amplifying calcium release. 6
Breakdown of bone matrix during osteolysis liberates growth factors that create a self‑reinforcing “vicious cycle” promoting further tumor growth and additional bone destruction. 6

Disseminated tumor cells colonize the hematopoietic stem‑cell niche of bone marrow and may remain dormant for years before re‑activation. 7
Upon activation, tumor cells secrete PTHrP, prostaglandins, and interleukins, which stimulate RANKL production and consequently osteoclast activation. 6
RANKL‑driven osteoclast activity leads to bone resorption, releasing calcium and bone‑derived growth factors into the circulation. 6
The released calcium and growth factors feed back to stimulate tumor cell proliferation, completing the self‑sustaining cycle of hypercalcemia and tumor progression. 6

Breast cancer – Approximately 70 % develop bone metastases; hypercalcemia commonly arises from extensive osteolytic lesions. 7
Multiple myeloma – Bone involvement occurs in about 95 % of cases, leading to hypercalcemia through widespread osteolytic destruction. 7
Renal cell carcinoma – Roughly 40 % develop bone metastases; many tumors produce PTHrP, resulting in humoral hypercalcemia. 7
Prostate cancer – Despite predominantly osteoblastic‑appearing lesions in ~85 % of patients with bone metastases, high underlying osteoclastic activity generates hypercalcemia, as evidenced by elevated bone‑resorption markers. 7

In breast cancer patients with bone metastases, the occurrence of skeletal‑related events—including hypercalcemia—reduces median survival to about 7 months, compared with 16 months for those with bone metastases alone. 8
Hypercalcemia often represents a paraneoplastic phenomenon that can manifest without any radiographically evident bone metastases, especially in tumors that secrete PTHrP. [8][6]
Squamous cell carcinomas may produce PTHrP and cause hypercalcemia even when imaging shows no bone involvement. [8][6]